These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 16386613)
1. Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. Aumente MD; Arizón JM; Segura J; López A; Albornoz R; Cárdenas M; Segura C Transplant Proc; 2005 Nov; 37(9):4014-7. PubMed ID: 16386613 [TBL] [Abstract][Full Text] [Related]
2. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients. Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566 [TBL] [Abstract][Full Text] [Related]
3. Cardiac allograft rejection: do trough cyclosporine levels correlate with the grade of histologic rejection? el Gamel A; Keevil B; Rahman A; Campbell C; Deiraniya A; Yonan N J Heart Lung Transplant; 1997 Mar; 16(3):268-74. PubMed ID: 9087869 [TBL] [Abstract][Full Text] [Related]
4. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation. Barnard JB; Thekkudan J; Richardson S; Bittar MN; Martyszczuck R; Hasan J; Khasati N; Keevil B; Yonan N J Heart Lung Transplant; 2006 May; 25(5):564-8. PubMed ID: 16678036 [TBL] [Abstract][Full Text] [Related]
5. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation]. Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420 [TBL] [Abstract][Full Text] [Related]
6. Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: insights from the Mycophenolate Steroid-Sparing Trial. Gotti E; Perico N; Gaspari F; Cattaneo D; Lesti MD; Ruggenenti P; Segoloni G; Salvadori M; Rigotti P; Valente U; Donati D; Sandrini S; Federico S; Sparacino V; Mourad G; Bosmans JL; Dimitrov BD; Iordache BE; Remuzzi G Transplant Proc; 2005 Jun; 37(5):2037-40. PubMed ID: 15964332 [TBL] [Abstract][Full Text] [Related]
7. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172 [TBL] [Abstract][Full Text] [Related]
8. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study. Iversen M; Nilsson F; Sipponen J; Eiskjaer H; Mared L; Bergan S; Nyström U; Fagertun HE; Solbu D; Simonsen S J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045 [TBL] [Abstract][Full Text] [Related]
9. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes. Delgado DH; Rao V; Hamel J; Miriuka S; Cusimano RJ; Ross HJ J Heart Lung Transplant; 2005 Sep; 24(9):1343-6. PubMed ID: 16143255 [TBL] [Abstract][Full Text] [Related]
10. Late acute cardiac allograft rejection: new therapeutic options? Schweiger M; Wasler A; Prenner G; Tripolt M; Schwarz M; Tscheliessnigg KH Transplant Proc; 2005 Dec; 37(10):4528-31. PubMed ID: 16387161 [TBL] [Abstract][Full Text] [Related]
11. Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in Taiwan. Chou NK; Chen RJ; Ko WJ; Lin HL; Yu SY; Chen YS; Hsu RB; Lee CM; Lin FY; Wang SS Transplant Proc; 2004 Oct; 36(8):2393-5. PubMed ID: 15561260 [TBL] [Abstract][Full Text] [Related]
16. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation. Min DI; Perry PJ; Chen HY; Hunsicker LG Pharmacotherapy; 1998; 18(2):282-7. PubMed ID: 9545147 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and side-effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients. Cantarovich M; Besner JG; Fitchett DH; Latter DA Clin Transplant; 1997 Oct; 11(5 Pt 1):399-405. PubMed ID: 9361930 [TBL] [Abstract][Full Text] [Related]
18. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117 [TBL] [Abstract][Full Text] [Related]
19. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients. Cantarovich M; Durrbach A; Hiesse C; Ladouceur M; Benoit G; Charpentier B Transplantation; 2008 Dec; 86(12):1732-7. PubMed ID: 19104413 [TBL] [Abstract][Full Text] [Related]
20. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. Akhlaghi F; Gonzalez L; Trull AK J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]